Novo Nordisk and Pfizer have revised their bids for Metsera, the obesity drug developer said on Tuesday. Novo's revised offer ...

This offer highlights Novo Nordisk’s commitment to investing in the US and interest in continuing to grow the scale of its US ...

Pfizer and Novo Nordisk have both offered to sweeten their bids for the US obesity biotech Metsera, in the latest development ...

Pfizer et Novo Nordisk se livrent une guerre de milliards pour se positionner sur le marché florissant des médicaments ...

Pfizer reported a drop in third-quarter profits Tuesday as lower sales of Covid-19 products more than offset gains in other ...

Gold Spot US Dollar, Pfizer Inc, US Dollar Index Futures, S&P 500 Futures. Read 's Market Analysis on Investing.com ...

Pfizer has increased its annual profit forecast and reported higher-than-expected profits for the third quarter amid a legal ...

The UK mandates housing for birds to curb bird flu. Philips surpasses profit expectations due to AI tools and tariff ...

Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales.

Pfizer has filed two separate lawsuits in an effort to stop Novo Nordisk's unsolicited bid to acquire obesity biotech Metsera ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Pfizer reported lower third-quarter profit and sales as demand for its Covid-19 vaccine and antiviral drug continue to decline. The drug maker posted net income of $3.54 billion, or 62 cents a share, ...